Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Q4 Revenues Jump 11 Percent on Strong Gene-Screening Business Growth

NEW YORK, Jan. 27 (GenomeWeb News) - Spurred by revenue in its Life and Analytical Sciences division, PerkinElmer's total receipts jumped 11 percent in the fourth quarter of 2004.

 

Total company revenue for the three months ended Dec. 31 shot up to $478 million from $431.8 million in the year-ago period. The Life and Analytical Sciences division saw revenue grow to $311 million in the fourth qurter of 2004 from $290 million in the same period last year -- a rise of 6.8 percent.

 

The company attributed the division's growth during the quarter to "double digit" revenue growth in its genetic-screening, -service and environmental businesses.

 

PerkinElmer's R&D expenses for the fourth quarter of 2004 were up $4.7 million to $23.6 million.

 

Net income grew 27 percent, as PerkinElmer reported $37.9 million for the fourth quarter of 2004, compared to $27.9 million year-over-year.

 

PerkinElmer had around $197.5 million in cash and equivalents as of Jan. 2.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.